Выбор редакции

More on Eli Lilly's (LLY) Q2: The 6% Y/Y rise in revenue comes despite a 25% drop in Zyprexa sales due to patent expirations. Cymbalta and Cialis sales rise 22% and 13% respectively. Stripping out currency effects, revenue growth is 8% with 6% attributable to higher prices and 2% to higher volume. U.S. sales rise 13% on higher Cymbalta prices. Gross margin rises 80 basis points Y/Y. Operating income is up 25% from Q2 2012. FY13 guidance is raised: $4.28-4.38/ share on revenue of $22.6-23.4B. Consensus is $3.92/ share on sales of $22.8B. Shares +3% premarket. (PR)

More on Eli Lilly's (LLY) Q2: The 6% Y/Y rise in revenue comes despite a 25% drop in Zyprexa sales due to patent expirations. Cymbalta and Cialis sales rise 22% and 13% respectively. Stripping out currency effects, revenue growth is 8% with 6% attributable to higher prices and 2% to higher volume. U.S. sales rise 13% on higher Cymbalta prices. Gross margin rises 80 basis points Y/Y. Operating income is up 25% from Q2 2012. FY13 guidance is raised: $4.28-4.38/ share on revenue of $22.6-23.4B. Consensus is $3.92/ share on sales of $22.8B. Shares +3% premarket. (PR) Post your comment!

НОВОСТИ ПО ТЕМЕ